Suchergebnisse - (Subject:"CK")

PubPharm (3.733)

1

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain) : a randomised, open-label, phase 2 trial

enthalten in: Lancet (London, England) | 2024

von Pérez-García, J. | Cortés, J. | Ruiz-Borrego, M. | +27

2

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01) : primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2024

von Smit, E. | Felip, E. | Uprety, D. | +17

3

Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials

enthalten in: Critical reviews in oncology/hematology | 2024

von Ma, R. | Shi, Y. | Yan, R. | +3

4

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer : Results from the drug rediscovery protocol (DRUP)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Spiekman, I. | Zeverijn, L. | Geurts, B. | +15

5

Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma : a pooled analysis of two phase I studies

enthalten in: Japanese journal of clinical oncology | 2024

von Takahashi, S. | Bando, H. | Kinoshita, I. | +9

6

Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer : a real-world retrospective single-institutional study in China

enthalten in: World journal of surgical oncology | 2024

von Peng, D. | Li, J. | Qiu, J. | +1

7

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?

enthalten in: JAMA oncology | 2024

von Sun, R. | Wei, L.

8

Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply

enthalten in: JAMA oncology | 2024

von Huober, J. | Thürlimann, B. | Dietrich, D.

9

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors : Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Connolly, R. | Wang, V. | Hyman, D. | +19

10

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

enthalten in: International journal of molecular sciences | 2024

von Franco-Mateos, E. | Souza-Egipsy, V. | García-Estévez, L. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[374]